Physician profile
Monica Wei
NPI 1417450214
$4,042.10
in general payments reported to CMS, 2019-2025
34 companies · $1,694 in 2025
The $1,694 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $279 · 2024: $2,069 · 2025: $1,694.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,042.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,042.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $845.24 | 2023-2025 | Krystexxa, Evenity, Enbrel |
| Abbvie INC. | $457.54 | 2023-2025 | Rinvoq |
| Octapharma USA, INC. | $340.60 | 2024-2025 | Octagam Immune Globulin (Human) |
| Boehringer Ingelheim Pharmaceuticals, INC. | $244.62 | 2024-2025 | Jardiance, Ofev, Cyltezo |
| Fresenius Kabi USA, LLC | $225.76 | 2024-2025 | Idacio, Adalimumab-Aacf |
| Ucb, INC. | $212.15 | 2023-2025 | Cimzia, Bimzelx |
| Aurinia Pharma U.S., INC. | $202.46 | 2024-2025 | Lupkynis |
| Pfizer INC. | $154.74 | 2024-2025 | |
| Radius Health, INC. | $136.81 | 2023-2025 | Tymlos |
| E.R. Squibb & Sons, L.L.C. | $130.68 | 2024-2025 | Orencia |
| Novartis Pharmaceuticals Corporation | $129.41 | 2024-2025 | |
| Dexcom, INC. | $126.95 | 2023-2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $111.98 | 2024-2025 | Benlysta, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $70.28 | 2023-2024 | |
| Alexion Pharmaceuticals, INC. | $59.61 | 2023-2024 | Strensiq |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $53.67 | 2025 | Rezdiffra |
| Sandoz INC. | $51.44 | 2024-2025 | Hyrimoz |
| Mannkind Corporation | $49.93 | 2023-2024 | Afrezza |
| Kiniksa Pharmaceuticals International, Plc | $49.65 | 2024 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $42.02 | 2024 | |
| United Therapeutics Corporation | $40.05 | 2023-2024 | Tyvaso |
| Genentech USA, INC. | $36.63 | 2025 | Actemra |
| Janssen Biotech, INC. | $34.91 | 2024 | Simponi Aria |
| Genzyme Corporation | $34.69 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.10 | 2023 | Takhzyro |
| Novo Nordisk INC | $22.36 | 2024 | Wegovy |
| Kyowa Kirin, INC. | $21.53 | 2024 | Crysvita |
| Scilex Pharmaceuticals INC. | $21.42 | 2024 | |
| Medtronic, INC. | $20.80 | 2025 | Minimed 780g |
| Chiesi USA, INC. | $19.24 | 2024 | Mycapssa |
| Tandem Diabetes Care, INC. | $18.66 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Biocon Biologics INC | $18.61 | 2025 | Yesintek |
| Averitas Pharma INC. | $18.24 | 2024 | Qutenza |
| Almatica Pharma LLC | $14.32 | 2025 | Loreev Xr, Teriparatide |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monica Wei listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.